Aridhia's Data Platform Used in Major European Research Collaboration to Tackle Alzheimer's Dementia

AridhiaAridhia has announced that it is among 36 organisations behind a ground-breaking Innovative Medicines Initiative research programme that aims to build a platform for efficient testing of innovative treatments for the prevention of Alzheimer's dementia.

Aridhia's data and analytics platform, AnalytiXagility, has been selected for use in the European Prevention of Alzheimer's Dementia (EPAD) project, a powerful research collaboration between European organisations in the public and private sectors which, unlike previous projects, focuses on prevention of dementia in the early stages of the disease.

The project will collaborate with existing cohorts to create a register, identifying 24,000 people across Europe who may be at risk of developing the disease later in life. 6,000 of these people will be invited to join EPAD's cohort of 'at risk' subjects to undergo standardised tests and follow-ups. Of these, approximately 1,500 people will be selected to take part in EPAD's proof of concept adaptive trials of innovative drugs.

Rodrigo Barnes, Chief Technology Officer at Aridhia, said that AnalytiXagility has been chosen because it offers a strong collaborative platform that is accessible to all of the consortium partners and is able to carry out advanced data analytics that can interrogate any kind of data.

"AnalytiXagility offers EPAD a flexible working environment that is collaborative, neutral and has the ability to carry out advanced data analytics during complex trials.

"It will be used as part of a trial engine for the EPAD cohort of 6,000 subjects and the further 1,500 participants who will be asked to take part in the project’s proof of concept adaptive trials of drug candidates or drug combinations that have been specially designed to prevent Alzheimer's dementia.

"With no cure for Alzheimer's and little in the way of treatment, it is vital that we understand and learn how to prevent Alzheimer’s dementia when in its early phases."

The University of Edinburgh is working with Aridhia to trial the EPAD cohort. Professor Craig Ritchie, one of the project’s co-ordinators who is based at the University said: "EPAD is a game-changing project. There is commitment from a wide range of organisations across academia, pharma and public health, to get to the root causes of dementia, to understand how the disease develops over the decades before symptoms become visible, and treat patients at an early stage."

"The EPAD model gives us the opportunity to work together to understand who is more likely the get the disease and how they can be treated early, and effectively."

EPAD promises to deliver a more efficient research model which can streamline the recruitment of patients and enable likely drug candidates to be accelerated straight into Phase III trials, the last stage before a new drug is licenced for use.

Furthermore, all data collected from the cohort will be made public to allow researchers the chance to improve their understanding of the disease, especially in pre-symptomatic phases.

Aridhia's involvement in EPAD cements its commitment to globally significant collaborative research projects, and to addressing one of society’s most challenging diseases. Earlier this year the company announced that AnalytiXagility has been chosen to underpin the three year Moneta Research project, supporting their research into identifying people most likely to develop Alzheimer's dementia.

About Aridhia Informatics
Founded in 2007, Aridhia is a world-leading clinical and translational informatics company developing technology and capability that accelerates the translation of precision medicine and biomedical research into clinical practice. Operating internationally on projects in England, Scotland, Australia, and across Europe, Aridhia works closely with governments, health organisations, research collaborations and academic institutions to transform how care is delivered.

Based in Edinburgh and Glasgow, Aridhia has a 60-strong multidisciplinary team of data scientists, information governance specialists, computer scientists, software developers and healthcare experts.

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Most Popular Now

SAP IoT Startup Accelerator

The SAP IoT Startup Accelerator is a structured co-innovation program for selected B2B startups focusing on the Internet of Things. The Accelerator helps startups grow and scale their businesses alongside...

Read more

Paving the Way for eHealth Interoperabil…

The EURO-CAS project launched operations today to deliver the eHealth Conformity Assessment Scheme for Europe in 2018. This scheme will help European health systems assess the conformity of eHealth products...

Read more

SkinVision Unveils Breakthrough Algorith…

Dutch mobile health startup SkinVision has revealed its new algorithm that can detect most common forms of deadly skin cancer. Previously focused on detecting melanoma skin cancer, the app can...

Read more

eHealth Hub Solution Match Call: Hospita…

Solution Match is one of the services offered by the EU-funded initiative eHealth Hub, intending to promote and boost up commercialization. The eHealth Hub aims to provide long-term support to...

Read more

Wearable AI System can Detect a Conversa…

It's a fact of nature that a single conversation can be interpreted in very different ways. For people with anxiety or conditions such as Asperger's, this can make social situations...

Read more

Doctrina Raises €1,020,000 of New Capita…

Doctrina, a start-up company transforming the traditional transfer of knowledge between pharmaceutical companies and pharmacies, has raised a total of €1,020,000 in series A funding. The investment will enable Doctrina...

Read more

Biovision World Life Science Forum 2017

4 - 6 April 2017, Lyon, France. Biovision World Life Science Forum is fostering a unique approach to meet, connect and collaborate between international decision-makers from the academic, civil society, policy-making...

Read more

DIY Live Cell Imaging Using a Smartphone

A recent study from Uppsala University shows how smartphones can be used to make movies of living cells, without the need for expensive equipment. The study is published in the...

Read more

Horder Healthcare Uses IMS MAXIMS Electr…

Healthcare provider Horder Healthcare is to deploy an electronic patient record (EPR) from software provider IMS MAXIMS, in order to improve care for thousands of patients and facilitate its digital...

Read more

Brain-Computer Interface Allows Complete…

A brain-computer interface that can decipher the thoughts of people who are unable to communicate could revolutionize the lives of those living with complete locked-in syndrome according to a new...

Read more

Deep Learning in Healthcare Summit

28 - 01 March 2017, London, UK. Discover advances in deep learning tools and techniques from the world's leading innovators across industry, academia and the healthcare sector. Learn from the experts...

Read more

Pitch Your Digital Health Solution at th…

The second eHealth Roadshow, promoted by the new EU-funded eHealth Hub project, will take place on the 6th of April in Stuttgart, Germany, in the frame of the Medtec Europe...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined